Загрузка...
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter. Approval came in March 2009 due to the positive results of the ATHENA trial showing significant reductions in all-cause mort...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2922313/ https://ncbi.nlm.nih.gov/pubmed/20730068 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|